Bioaccell is a Kyoto-based contract cell processing company that cultivates therapeutic immune cells for medical institutions. It provides certified cell culture services for cancer immunotherapy.
A startup from Tokushima University providing genome-editing-based precision breeding services for agriculture and livestock, as well as contract testing for researchers. It accelerates industrial breeding and contributes to solving challenges through the power of biology.
A startup advancing drug discovery through proprietary platform technology that selectively delivers drugs to immune cells, both through in-house development and collaborative partnerships. It aims to create novel therapies for intractable diseases by controlling immune responses.
Remohab is a medical device startup from Osaka University, working on the development of a remote cardiac rehabilitation system. As the first company in the Japan Bio design Program, its participation in Air Water Group is the first M&A exit case in Japan in the DTx (Digital Therapeutics) field. In 2024, its completed Japan’s first physician-initiated Phase III clinical trial for a remote cardiac rehabilitation system, and on June 23, 2025, its product “Remohab CR U” received approval from the Pharmaceuticals and Medical Devices Agency (PMDA). Remohab aims to launch the product in Japan first and promote its nationwide adoption with future global expansion in mind.
A startup developing a tooth regeneration drug that enables the regeneration of missing teeth in congenital anodontia by utilizing neutralizing antibodies that suppress molecules inhibiting tooth germ growth.